Replimune Group, Inc. (REPL)
NASDAQ$11.78
Market Cap
$907.23M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
805 of 924
Rank in Industry
455 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
REPL Insider Trading Activity
REPL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,103,143 | 12 | 100 |
Related Transactions
| Schwendenman Andrew | Chief Accounting Officer | 0 | $0 | 1 | $14,868 | $-14,868 |
| Sarchi Christopher | Chief Commercial Officer | 0 | $0 | 2 | $70,482 | $-70,482 |
| Coffin Robert | director | 0 | $0 | 1 | $74,172 | $-74,172 |
| Hill Emily Luisa | Chief Financial Officer | 0 | $0 | 1 | $90,989 | $-90,989 |
| Love Colin | Chief Operating Officer | 0 | $0 | 1 | $113,969 | $-113,969 |
| Xynos Konstantinos | Chief Medical Officer | 0 | $0 | 3 | $238,414 | $-238,414 |
| Astley-Sparke Philip | Executive Chairman | 0 | $0 | 1 | $245,394 | $-245,394 |
| Patel Sushil | Chief Executive Officer | 0 | $0 | 2 | $254,855 | $-254,855 |
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing …
Insider Activity of Replimune Group, Inc.
Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $1.1M worth of Replimune Group, Inc. stock.
On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $0 and sold $15.69M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.
List of Insider Buy and Sell Transactions, Replimune Group, Inc.
| 2024-12-16 | Sale | Patel Sushil | Chief Executive Officer | 10,000 0.0132% | $12.42 | $124,200 | +0.40% | |
| 2024-11-18 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,246 0.0106% | $10.78 | $78,112 | +17.36% | |
| 2024-11-18 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,207 0.0076% | $10.78 | $56,131 | +17.36% | |
| 2024-08-16 | Sale | Hill Emily Luisa | Chief Financial Officer | 8,938 0.0137% | $10.18 | $90,989 | +18.00% | |
| 2024-06-07 | Sale | Xynos Konstantinos | Chief Medical Officer | 15,881 0.0245% | $7.50 | $119,108 | +43.54% | |
| 2024-05-16 | Sale | Coffin Robert | director | 11,464 0.0189% | $6.47 | $74,172 | +65.63% | |
| 2024-05-16 | Sale | Astley-Sparke Philip | Executive Chairman | 37,928 0.0626% | $6.47 | $245,394 | +65.63% | |
| 2024-05-16 | Sale | Love Colin | Chief Operating Officer | 17,615 0.0291% | $6.47 | $113,969 | +65.63% | |
| 2024-05-16 | Sale | Patel Sushil | Chief Executive Officer | 20,194 0.0333% | $6.47 | $130,655 | +65.63% | |
| 2024-05-16 | Sale | Xynos Konstantinos | Chief Medical Officer | 6,367 0.0105% | $6.47 | $41,194 | +65.63% | |
| 2024-05-16 | Sale | Sarchi Christopher | Chief Commercial Officer | 2,218 0.0037% | $6.47 | $14,350 | +65.63% | |
| 2024-05-16 | Sale | Schwendenman Andrew | Chief Accounting Officer | 2,298 0.0038% | $6.47 | $14,868 | +65.63% | |
| 2023-11-16 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,313 0.0131% | $10.92 | $79,858 | -15.60% | |
| 2023-11-16 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,255 0.0094% | $10.92 | $57,385 | -15.60% | |
| 2023-09-12 | Sale | Esposito Pamela | Chief Business Officer | 300 0.0005% | $20.00 | $6,000 | -54.46% | |
| 2023-09-11 | Sale | Esposito Pamela | Chief Business Officer | 5,358 0.0092% | $20.01 | $107,214 | -55.86% | |
| 2023-08-22 | Sale | Esposito Pamela | Chief Business Officer | 18,600 0.0315% | $20.01 | $372,186 | -56.41% | |
| 2023-08-11 | Sale | Esposito Pamela | Chief Business Officer | 1,400 0.0024% | $20.00 | $28,000 | -56.32% | |
| 2023-07-10 | Sale | Esposito Pamela | Chief Business Officer | 20,000 0.035% | $21.58 | $431,541 | -58.78% | |
| 2023-06-13 | Sale | Patel Sushil | Chief Strategy Officer | 5,698 0.0098% | $24.05 | $137,008 | -62.63% |
Total: 131
*Gray background shows transactions not older than one year
Insider Historical Profitability
12.92%
| Omega Fund IV, L.P. | 4763380 6.185% | $56.11M | 2 | 20 | +27.98% | |
| Slootweg Hugo Alexander | 4721449 6.1306% | $55.62M | 1 | 0 | <0.0001% | |
| Forbion Capital Fund III Cooperatief U.A. | 10 percent owner | 4721449 6.1306% | $55.62M | 1 | 0 | <0.0001% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2838968 3.6863% | $33.44M | 1 | 0 | <0.0001% |
| Rhodes Jason P | director | 946000 1.2283% | $11.14M | 1 | 11 | +63.12% |
Historical Insider Profitability vs. Competitors
$7,929,017 | 58 | 21.56% | $788.11M | |
$571,084,134 | 44 | 4.33% | $968.45M | |
$97,176 | 41 | 42.84% | $782.59M | |
$530,111,731 | 35 | 8.67% | $1.1B | |
$28,907,358 | 35 | 41.41% | $914.6M |
REPL Institutional Investors: Active Positions
| Increased Positions | 101 | +78.91% | 16M | +22.93% |
| Decreased Positions | 50 | -39.06% | 6M | -8.91% |
| New Positions | 35 | New | 6M | New |
| Sold Out Positions | 19 | Sold Out | 1M | Sold Out |
| Total Postitions | 179 | +39.84% | 80M | +14.02% |
REPL Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Baker Bros. Advisors Lp | $128,733.00 | 14.35% | 11.05M | 0 | 0% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $127,772.00 | 14.24% | 10.96M | +1M | +10.97% | 2024-12-31 |
| Blackrock, Inc. | $64,876.00 | 7.23% | 5.57M | +94,833 | +1.73% | 2024-12-31 |
| Redmile Group, Llc | $57,174.00 | 6.37% | 4.91M | +124,344 | +2.6% | 2024-12-31 |
| Fcpm Iii Services B.V. | $46,278.00 | 5.16% | 3.97M | -895,781 | -18.41% | 2024-12-31 |
| Vanguard Group Inc | $41,910.00 | 4.67% | 3.6M | +129,601 | +3.74% | 2024-12-31 |
| Sofinnova Investments, Inc. | $36,708.00 | 4.09% | 3.15M | +3M | +6,442.69% | 2024-12-31 |
| Tang Capital Management Llc | $31,469.00 | 3.51% | 2.7M | +2M | +125% | 2024-12-31 |
| State Street Corp | $25,688.00 | 2.86% | 2.2M | -135,991 | -5.81% | 2024-12-31 |
| Rtw Investments, Lp | $24,068.00 | 2.68% | 2.07M | +931,223 | +82.13% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.